produc
tissu
injuri
encourag
viru
persist
attract
extens
interest
recent
year
interact
inevit
intric
ad
fundament
complex
immun
respons
complic
natur
virus
antigen
intracellular
site
abil
replic
multipl
separ
antigen
molecul
case
abil
infect
replic
lymphocyt
macrophag
precursor
cell
number
immunolog
mechan
defin
virusinfect
cell
kill
vitro
antibodyindepend
cellmedi
cytotox
viru
infect
target
cell
receiv
great
attent
especi
last
year
sinc
demonstr
kill
virusinfect
cell
specif
sensit
cytotox
cell
occur
restrict
mous
subject
recent
review
seri
zinkernagel
doherti
even
recent
spontan
cytotox
murin
human
lymphocyt
virusinfect
target
uninfect
target
tumor
cell
line
becom
subject
intens
investig
demonstr
activ
natur
killer
cell
appar
augment
interferon
topic
pertain
virusinfect
cell
review
murin
welsh
human
santoli
koprowski
system
serum
antibodi
produc
respons
viru
infect
major
import
prevent
spread
infect
b
virtu
neutral
free
viru
extracellular
fluid
review
daniel
burn
allison
viru
neutral
antibodi
enhanc
complement
antibodi
complement
lyse
envelop
virion
complement
may
lyse
neutral
virus
absenc
antibodi
review
cooper
cooper
welsh
antibodi
also
act
number
way
virusinfect
cell
review
concern
effect
immun
respons
virusinfect
cell
mediat
antibodi
deal
action
antibodi
alon
antibodi
complement
antibodi
interact
cytotox
cell
virusinfect
target
cell
becom
appar
despit
forego
emphasi
role
antibodi
neutral
free
viru
cytotox
cell
kill
virusinfect
cell
antibodi
profoundli
affect
virusinfect
cell
vitro
littl
reason
think
action
may
less
import
vivo
cytotox
mechan
demonstr
vitro
furthermor
cytotox
cell
antibodymedi
effect
virusinfect
cell
occur
prior
releas
progeni
viru
elimin
sourc
continu
viru
product
survey
subject
emphasi
given
effect
antibodi
virusinfect
cell
homolog
human
system
particularli
section
iv
work
laboratori
aspect
mechan
viral
protein
express
surfac
infect
cell
merit
discuss
target
antigen
whose
recognit
initi
immun
lysi
envelop
rna
virus
acquir
outer
lipid
envelop
bud
host
cell
plasma
membran
express
viral
glycoprotein
cell
surfac
group
compris
part
togavirus
neg
strand
rna
virus
arena
rhabdo
orthomyxo
paramyxovirus
retrovirus
dna
virus
herp
virus
bud
nuclear
membran
poxvirus
manufactur
envelop
also
express
structur
viral
glycoprotein
cell
surfac
addit
viru
infect
may
caus
express
nonstructur
viral
protein
eg
tumorspecif
transplant
antigen
alter
express
host
membran
protein
worthwhil
briefli
summar
mechan
assembl
envelop
virus
viral
entri
cell
uncoat
transcript
viral
mrna
translat
viral
protein
host
cell
ribosom
follow
envelop
virus
three
main
class
structur
protein
nucleocapsid
protein
matrix
protein
envelop
glycoprotein
nucleocapsid
protein
associ
viral
nucleic
acid
protein
present
togavirus
peripher
membran
protein
associ
cytoplasm
surfac
cell
membran
see
choppin
compan
glycoprotein
insert
lipid
bilay
plasma
membran
probabl
transmembran
protein
hydrophob
region
vsv
glycoprotein
provid
model
process
rothman
lodish
briefli
nascent
polypeptid
chain
synthes
membraneassoci
polyribosom
insert
membran
endoplasm
reticulum
insert
appar
mediat
specif
signal
peptid
sequenc
chain
accord
signal
hypothesi
dobberstein
glycosyl
occur
noncytoplasm
side
membran
util
host
cell
glycosyl
enzym
protein
transport
plasma
membran
vesicl
fuse
membran
viral
glycoprotein
appear
mobil
lipid
bilay
host
cell
integr
membran
protein
see
section
becom
distribut
random
surfac
cell
prior
process
bud
glycoprotein
locat
area
bud
protein
align
glycoprotein
cytoplasm
side
membran
nucleocapsid
also
align
protein
whole
complex
envelop
bud
plasma
membran
virion
cell
glycoprotein
thu
expos
viral
protein
lipid
envelop
reflect
composit
cell
plasma
membran
deriv
lenard
compan
evid
indic
host
cell
membran
protein
almost
total
exclud
viral
envelop
bud
see
holland
kiehn
circumstanti
evid
antigen
incorpor
friend
leukemia
viru
flv
bubber
lilli
base
adsorpt
antisera
flv
purifi
vireni
mice
howev
viru
disrupt
demonstr
adsorpt
yet
firm
confirmatori
biochem
evid
demonstr
incorpor
gene
product
major
histocompat
complex
mhc
envelop
virus
seem
definit
cellular
actin
peripher
membran
protein
incorpor
envelop
virus
eg
measl
viru
vsv
influenza
viru
demonstr
presenc
purifi
virion
howev
probabl
passiv
associ
exposur
infect
cell
cytochalasin
b
prevent
incorpor
actin
vsv
influenza
virion
inhibit
bud
griffin
compan
henc
contractil
protein
function
appar
requir
bud
process
virus
may
circumst
bud
particular
domain
plasma
membran
studi
two
differ
cultur
line
epitheli
cell
grown
monolay
boulan
sabatini
found
influenza
viru
simian
viru
sendai
viru
bud
exclus
apic
free
surfac
wherea
vsv
bud
basolater
plasma
membran
impli
certain
virus
might
less
suscept
immun
recognit
cell
surfac
bud
area
cell
remov
direct
contact
blood
point
worth
make
virus
must
express
virusspecif
protein
cell
membran
releas
free
virion
occur
also
appar
lysi
cell
infect
bud
viru
would
unlik
result
releas
infecti
viru
nucleocapsid
would
devoid
envelop
glycoprotein
mediat
virion
attach
cell
membran
prior
entri
herp
simplex
virus
hsv
wide
use
uitro
cytotox
studi
structur
much
complex
code
viral
polypeptid
roizman
furlong
viral
protein
insert
cytoplasm
plasma
membran
viral
core
gain
envelop
bud
mem
brane
intrigu
featur
hsv
abil
induc
appear
fc
receptor
human
rabbit
igg
membran
infect
cell
watkin
westmoreland
watkin
although
structur
relationship
receptor
endogen
fc
receptor
lymphocyt
phagocyt
cell
unknown
seem
possibl
virusencod
gene
product
reportedli
block
f
ab
antibodi
hsv
mctaggart
et
al
adler
et
al
also
report
cytomegaloviru
induc
fc
receptor
infect
cell
rahman
et
al
westmoreland
et
al
remain
seen
whether
novel
surfac
structur
particip
definit
way
immunolog
reaction
preliminari
evid
indic
may
summar
section
unlik
dna
virus
poxvirus
replic
cytoplasm
rather
nucleu
unlik
bud
virus
synthes
lipid
membran
nevertheless
express
viral
antigen
cell
surfac
appear
earli
hour
infect
ada
et
al
studi
polioviru
rabbit
svehag
mandel
human
ogra
et
al
show
similar
sequenc
develop
antibodi
respons
describ
viral
nonvir
antigen
immun
level
neutral
igm
antibodi
attain
maxim
titer
week
undetect
month
igg
titer
rise
parallel
continu
increas
sever
month
persist
lower
level
year
serum
iga
antibodi
first
detect
sever
week
immun
titer
rise
sever
month
secretori
iga
respons
occur
local
site
infect
mucos
surfac
live
viru
subsequ
challeng
viru
elicit
transient
igm
addit
continu
igg
respons
studi
number
virus
show
similar
pattern
respons
mani
viral
antigen
appear
thymu
depend
indic
elicit
antibodi
small
amount
igm
antibodi
nude
mice
burn
et
al
review
oldston
although
studi
immun
respons
antibodi
measur
neutral
antibodi
like
antibodi
also
recogn
antigen
infect
cell
neutral
antibodi
direct
extern
protein
virion
like
express
also
infect
cell
membran
much
work
rel
import
respons
individu
viral
antigen
done
influenza
viru
larg
biochemistri
influenza
viru
includ
detail
knowledg
structur
glycoprotein
better
understood
virus
passiv
transfer
antibodi
nucleoprotein
intern
polypeptid
protect
infect
mice
wherea
transfer
antibodi
hemagglutinin
ha
lesser
extent
neuraminidas
protect
see
virelizi
et
al
direct
visual
bromelainextract
influenza
ha
reaction
igg
antibodi
electron
microscopi
show
antibodi
react
tip
moleculeth
end
spike
farthest
membran
virion
cell
membran
wrigley
et
nl
site
ha
like
steric
access
antibodi
virion
paramyxovirus
rel
respons
two
envelop
protein
may
import
effect
immun
norrbi
associ
norrbi
et
al
norrbi
penttinen
show
formalininactiv
mump
vaccin
tween
measl
vaccin
induc
antibodi
viral
ha
fusion
f
protein
hemolysin
compar
immun
live
attenu
virus
induc
antibodi
f
protein
case
measl
viru
exposur
wildtyp
viru
immun
inactiv
viru
sometim
produc
clinic
syndrom
atyp
measl
promin
pulmonari
infiltr
sever
rash
inactiv
vaccin
gener
produc
poor
level
immun
extens
literatur
subject
humor
immun
respons
viral
antigen
review
ogra
et
bum
allison
absenc
effector
system
complement
antibodydepend
cytotox
k
cell
antibodi
act
virusinfect
cell
affect
releas
progeni
viru
express
viral
antigen
action
appear
least
partial
revers
circumst
capabl
protect
infect
cell
subsequ
immunolog
attack
antibodyinduc
redistribut
surfac
viral
antigen
phenomenon
cap
integr
membran
protein
antibodi
lectin
well
describ
bind
antibodi
initi
caus
patch
antigen
follow
polar
redistribut
crosslink
membran
protein
cap
initi
patch
energi
independ
wherea
cap
temperatur
energi
depend
involv
particip
cell
contractil
protein
dival
antibodi
requir
produc
cap
bind
antibodi
appear
induc
transmembran
linkag
integr
membran
protein
intracellular
actomyosincontain
filament
patch
stage
cell
suspens
bourgignon
singer
monolay
ash
et
al
integr
membran
protein
behav
way
subject
appli
b
lymphocyt
review
seri
schreiner
unanu
viral
glycoprotein
express
cell
membran
also
cap
antibodi
shown
independ
measl
joseph
oldston
lampert
et
al
ehrnst
sundquist
influenza
rutter
mannweil
subsequ
virus
cap
measl
viral
glycoprotein
requir
activ
cell
metabol
function
cytoskeleton
membran
atp
dival
antibodi
joseph
oldston
see
tabl
glycoprotein
thu
capabl
later
diffus
membran
behav
respect
host
cell
integr
membran
protein
fig
electron
microscopi
studi
measl
virusinfect
cell
show
nucleocapsid
move
concert
glycoprotein
cytoplasm
side
membran
latter
cap
lampert
et
al
indic
transmembran
connect
exist
surfac
intern
polypeptid
studi
use
fluorescein
monospecif
antisera
low
concentr
cytochalasin
b
report
prevent
associ
movement
nucleocapsid
tyrel
ehrnst
moredetail
studi
need
deter
joseph
oldston
cell
preincub
inhibitor
minut
fitc
conjug
antibodi
measl
hour
mine
whether
separ
viral
envelop
glycoprotein
speci
express
membran
cocap
whether
behav
independ
molecul
evid
whether
host
cell
membran
protein
particularli
product
mhc
gene
cocap
viral
protein
somewhat
contradictori
partli
owe
studi
differ
system
antisera
rauscher
viru
initi
report
cocap
tumor
cell
schrader
et
al
later
use
well
defin
antisera
found
retrovir
cocap
tl
mous
thymoma
line
bourgignon
et
al
howev
studi
cap
host
cell
surfac
glycoprotein
also
induc
cocap
thi
tl
antigen
suggest
antigen
may
cocap
varieti
independ
cell
surfac
molecul
possibl
postul
report
link
actomyosin
filament
bourgignon
et
al
oldston
unpublish
observ
furthermor
recent
care
biochem
studi
use
immunoprecipit
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
evid
molecular
associ
mhc
molecul
moloney
viru
could
found
moloney
viru
lymphoma
line
fox
weissman
one
major
interest
observ
relev
debat
whether
cytotox
cell
recogn
mhc
product
viral
antigen
complex
two
independ
molecul
see
zinkernagel
doherti
context
addit
evid
argu
direct
molecular
associ
antigen
viral
glycoprotein
least
occur
transcript
translat
provid
b
experi
mix
independ
synthes
protein
thu
secondari
uitro
cytotox
cell
respons
gener
liposom
contain
isol
antigen
sendai
viral
glycoprotein
finberget
al
heterokaryon
form
fuse
cell
bear
antigen
inappropri
antigen
uninfect
cell
appropri
haplotyp
report
act
target
restrict
cytotox
cell
watt
good
could
explain
dival
antibodi
bind
ha
steric
hinder
access
antibodi
f
sisson
et
al
gent
solubil
materi
bind
staphylococc
protein
analyz
sdspage
igg
antibodi
bound
viral
glycoprotein
cell
infect
hour
later
stage
infect
antivir
igc
f
ab
bound
ha
glycoprotein
wherea
amount
fab
bound
ha
f
glycoprotein
fig
find
interpret
show
high
densiti
antigen
dival
antibodi
ha
could
steric
block
access
antibodi
f
cell
surfac
studi
actual
bind
site
antibodi
infect
cell
surfac
would
interest
regard
virus
antigen
modul
term
origin
introduc
boys
et
al
describ
revers
loss
tl
thymic
leukemia
antigen
phenotyp
tl
leukemia
cell
passag
immun
mice
cell
lost
sensit
lysi
new
sourc
antitl
antibodi
guinea
pig
complement
ad
tl
phenotyp
suscept
lysi
return
cultur
absenc
antibodi
passag
unimmun
mice
antigen
modul
tl
tumor
system
review
detail
stackpol
jacobson
seem
similar
phenomenon
occur
virusinfect
cell
expos
antibodi
although
mechan
may
necessarili
precis
ident
tl
system
joseph
oldston
found
cultur
measl
virusinfect
hela
cell
presenc
antibodi
measl
viru
render
resist
lysi
expos
fresh
sourc
human
antibodi
human
complement
author
term
antibodyinduc
viral
antigen
modul
antibodyinduc
measl
viru
antigen
modul
subsequ
studi
detail
hela
cell
persist
acut
infect
measl
viru
incub
heatinactiv
human
serum
contain
antibodi
measl
viru
maintain
suspens
cultur
heatinactiv
human
serum
time
point
cell
remov
cultur
wash
infect
cell
suscept
lysi
human
antivir
antibodi
complement
underw
progress
declin
maxim
hour
correl
loss
access
viral
antigen
cell
surfac
detect
surfac
stain
fluorescein
antimeasl
igg
bind
radiolabel
antibodi
see
fig
initi
hour
cultur
presenc
antibodi
minim
degre
cap
format
evid
measlesinfect
cell
acut
infect
cell
maintain
cultur
regain
suscept
lysi
hour
wherea
persist
infect
hela
cell
regain
suscept
wash
recultur
absenc
antibodi
differ
probabl
reflect
differ
rate
densiti
viral
glycoprotein
synthesi
two
cell
type
acut
infect
cell
synthes
enough
viral
antigen
eventu
bind
antibodi
experiment
system
use
escap
modul
condit
cell
persist
infect
measl
viru
complet
lost
suscept
lysi
peripher
blood
lymphocyt
immun
subject
within
day
cultur
oldston
tishon
cultur
cell
infect
measl
viru
longer
period
presenc
antibodi
result
select
attenu
viru
rustigian
gould
almeida
although
biochem
structur
select
virus
examin
care
fate
viru
antigenantibodi
complex
infect
cell
import
understand
mechan
antigen
modul
gener
approach
use
studi
ligand
interact
cell
surfac
molecul
label
one
compon
complex
follow
fate
igg
antibodi
bound
surfac
measl
virusinfect
cell
start
cultur
period
condit
describ
antigen
modul
radioact
still
cell
associ
hour
nearli
protein
bound
perrin
oldston
fate
antibodi
follow
detail
perrin
oldston
hour
cultur
present
supernat
analysi
linear
sucros
densiti
gradient
show
third
label
igg
sediment
peak
heavier
igg
peak
heavier
igg
also
contain
measl
viru
ha
nucleocapsid
detect
immunoprecipit
specif
antibodi
materi
peak
bound
rheumatoid
factor
clq
raji
cell
indic
presenc
immun
complex
thu
find
suggest
signific
amount
complex
antibodi
viral
glycoprotein
shed
cell
surfac
absenc
nucleocapsid
indic
antibodi
unlik
complex
whole
viru
contrast
small
amount
antibodi
appear
endocytos
shown
studi
cell
lysat
sd
nontca
precipit
materi
present
suggest
intracellular
degrad
lysosom
perrin
oldston
immunoelectron
microscopi
studi
measlesinfect
cell
cap
igg
antibodi
measl
label
peroxidas
conjug
antiigg
rare
show
intern
peroxidas
lampert
et
al
henc
endocytosi
viral
antigenantibodi
complex
appear
unusu
durat
latter
experi
account
minor
complex
longer
interv
modul
condit
studi
perrin
oldston
endocytosi
peroxidas
label
seen
electron
microscopi
studi
antibodytr
measlesinfect
syncyti
cell
p
w
lampert
howev
use
second
peroxidasecoupl
antibodi
shown
favor
endocytosi
membran
protein
least
b
lymphocyt
schreiner
unanu
make
system
artifici
compar
situat
uiuo
recent
experi
fate
viral
cell
surfac
antigen
follow
surfac
radioiodin
measl
virusinfect
cell
mainten
cell
cultur
without
antibodi
rate
disappear
viral
glycoprotein
cell
determin
run
cell
lysat
sdspage
excis
count
viral
glycoprotein
band
initi
acceler
turnov
rate
label
viral
glycoprotein
cell
cultur
antivir
antibodi
greater
cell
cultur
absenc
antibodi
suggest
initi
shed
antibodi
subsequ
enhanc
net
rate
viral
glycoprotein
loss
cell
cultur
condit
use
contrast
fate
viral
antigenantibodi
complex
plasma
membran
ligand
interact
surfac
ig
fc
receptor
b
lymphocyt
result
primarili
endocytosi
review
schreiner
unanu
fate
cell
surfac
molecul
complex
antibodi
less
defin
although
appear
mhc
molecul
b
cell
less
like
endocytos
may
shed
unanu
et
al
review
b
schreiner
unanu
viral
system
antigen
modul
studi
involv
oncogen
murin
retrovirus
gross
viru
leukemia
antigen
modul
vivo
immun
mice
aoki
johnson
vitro
ioachim
sabbath
shown
resist
antibodi
complementdepend
lysi
also
evid
antigen
modul
flvinduc
leukemia
demonstr
vitro
flvinfect
cell
genovesi
et
al
like
play
role
uiuo
doig
cheseboro
presenc
antivir
antibodi
loss
flv
antigen
leukem
cell
surfac
recoveri
viremia
associ
singl
genet
locu
name
link
mhc
suggest
act
immunoregulatori
gene
influenc
product
cytotox
antiflv
antibodi
nevertheless
despit
evid
antigen
modul
progress
fatal
leukemia
occur
unless
appropri
separ
gene
influenc
recoveri
leukemia
associ
locu
doig
cheseboro
mous
mammari
tumor
viru
antigen
also
specif
modul
vitro
calafat
et
al
shed
viral
antigenantibodi
complex
also
promin
studi
assess
immunoelectron
microscopi
studi
review
antibodi
medium
infect
cultur
cell
result
decreas
detect
viru
medium
caus
part
complex
antibodi
free
viru
releas
cell
also
crosslink
viral
glycoprotein
cell
surfac
antibodi
therebi
inhibit
releas
viru
probabl
interf
synthesi
express
viral
protein
bud
process
releas
influenza
viru
inhibit
antibodi
ha
less
effect
antibodi
neuraminidas
dowdl
et
uz
fab
fragment
antivir
igg
earlier
report
inhibit
releas
viru
becht
et
ul
addit
effect
antibodi
releas
viru
evid
suggest
antibodi
may
also
affect
synthesi
andor
express
viral
protein
insid
cell
studi
compar
control
found
express
f
protein
diminish
detect
decreas
incorpor
slmethionin
sinc
turnov
f
protein
cell
surfac
appreci
acceler
fujinami
et
observ
like
repres
diminish
synthesi
f
protein
interestingli
express
cytoplasm
viral
polypeptid
measl
viru
phosphoprotein
p
also
diminish
assess
methionin
incorpor
see
fig
p
protein
associ
transcript
complex
probabl
necessari
replic
viral
genom
mountcastl
choppin
effect
specif
antivir
antibodi
could
produc
exclus
purifi
antivir
igg
incub
antibodi
hela
cell
surfac
nonimmun
igg
henc
regul
intern
viral
polypeptid
antibodi
initi
present
outsid
cell
occur
whether
transmembran
signal
produc
antibodi
bind
plasma
membran
whether
effect
mediat
pinocytos
antibodi
act
insid
cell
known
yagi
et
al
observ
chang
polypeptid
profil
mous
mammari
tumor
viru
tumor
cell
cultur
presenc
antibodi
vitro
although
chang
analyz
detail
regard
individu
protein
evid
antibodi
inhibit
viral
transcript
translat
cellfre
system
thu
antibodi
vsv
viral
transcriptas
immedi
inhibit
rna
transcript
vsv
nucleocapsid
imblum
wagner
antibodi
newcastl
diseas
viru
nucleocapsid
effect
miller
stone
result
presum
produc
direct
bind
antibodi
viral
enzym
may
use
tool
molecular
virolog
howev
observ
antibodi
affect
viral
polypeptid
express
prior
label
cell
incub
without
antibodi
hour
p
protein
f
seen
major
reduct
fragment
reduc
cell
cultur
antibodi
peak
found
uninfect
cell
migrat
probabl
repres
cellular
actin
p
found
insid
cell
f
express
cell
surfac
fujinami
oldston
intact
cultur
cell
suggest
synthesi
transport
assembl
viral
polypeptid
could
significantli
affect
antibodi
uiuo
hsv
cytomegaloviru
induc
format
fc
receptor
igg
surfac
infect
cell
costa
et
al
cultur
vero
cell
infect
presenc
nonimmun
rabbit
igg
fc
fragment
concentr
mgml
found
mark
reduct
viru
product
sinc
igg
neutral
effect
free
viru
cytotox
effect
infect
cell
suggest
bind
fc
receptor
inhibit
growth
virusinduc
fc
recptor
hsv
costa
et
al
record
effect
f
ab
fragment
igg
prepar
virusinfect
cell
adler
et
al
report
preincub
infect
rat
neuroma
cell
aggreg
nonimmun
igg
result
loss
suscept
lysi
antibodi
complement
effect
nativ
nonaggreg
igg
report
although
report
mention
cap
observ
fitcaggreg
igg
use
systemat
studi
fate
hsv
fc
receptor
bind
igg
contrast
ragerzisman
et
al
report
aggreg
nonimmun
igg
could
mediat
cytotox
hsvinfect
cell
normal
mous
periton
macrophag
author
postul
caus
crosslink
fc
receptor
hsvinfect
target
effector
cytotox
cell
aggreg
igg
report
thu
suggest
presenc
hsv
fc
receptor
may
inhibit
viral
replic
one
hand
might
interfer
enhanc
immun
cytolysi
clearli
detail
studi
system
warrant
presenc
hsv
fc
receptor
must
taken
account
assess
immun
cytolysi
herp
virusinfect
cell
antibodi
bind
surfac
virusinfect
cell
affect
viru
product
releas
absenc
effector
system
complex
dynam
interact
exist
antibodi
viral
polypeptid
express
plasma
membran
clearli
antibodi
induc
redistribut
cap
viral
protein
cell
surfac
measl
viral
antigen
antibodi
complex
plasma
membran
subsequ
shed
rather
endocytos
howev
difficult
know
whether
shed
complex
like
occur
viral
membran
protein
cell
surfac
membran
protein
although
iggantiigg
complex
b
lymphocyt
membran
predominantli
endocytos
may
peculiar
signal
b
cell
host
membran
protein
complex
ligand
may
rapidli
endocytos
endocytosi
subsequ
degrad
lysosom
believ
normal
rout
metabol
host
cell
membran
protein
indic
studi
surfac
radioiodin
mous
l
cell
hubbard
cohn
hormon
receptor
complex
specif
ligand
probabl
endocytos
degrad
way
catt
et
ol
viral
glycoprotein
destin
export
membran
may
suscept
shed
actual
segment
membran
viru
bud
commenc
might
even
like
electron
microscop
studi
measl
virusinfect
cell
undergo
cap
show
bud
viru
visibl
microvilli
form
cap
lampert
ul
antibodyinduc
viral
antigen
modul
describ
measl
virusinfect
cell
similar
origin
tl
system
boys
et
al
henc
cap
essenti
antibodi
viral
antigen
still
present
cell
time
maxim
resist
antibodyand
complementmedi
lysi
howev
yu
cohen
could
detect
chang
tl
synthesi
tl
cell
undergo
modul
show
surfac
radioiodin
acceler
remov
l
cell
surfac
least
earli
time
cours
modul
contrast
diminish
synthesi
may
contribut
loss
surfac
viral
antigen
presenc
antibodi
measl
virusinfect
cell
suggest
requir
produc
modul
measl
virusinfect
cell
wherea
one
tl
system
may
conclud
loss
surfac
viral
antigen
induc
antibodi
lead
antigen
modul
could
result
combin
u
shed
antigen
antibodi
complex
b
block
antigen
site
igg
remain
membran
c
diminut
synthesi
surfac
viral
polypeptid
cell
gener
render
resist
lysi
antibodi
complement
via
rel
modest
reduct
surfac
antigen
import
note
addit
resist
antibodydepend
complenientmedi
lysi
modul
measl
virusinfect
cell
also
resist
antibodydepend
cellmedi
cytotox
oldston
tishon
antibodi
bind
intact
cell
affect
intracellular
express
viral
polypeptid
shown
measl
virusinfect
hela
cell
fujinami
oldston
area
begun
studi
biochem
level
interest
see
parallel
contrast
aris
membran
receptorligand
interact
hormon
receptor
major
interest
observ
lie
possibl
effect
antibodi
may
repres
mechan
wherebi
viru
persist
could
establish
vivo
consequ
would
cell
render
resist
immun
injuri
lost
surfac
viral
marker
still
retain
potenti
shed
viru
antibodi
remov
infect
adjac
cell
celltocel
spread
possibl
discuss
section
vi
virusinfect
cell
lyse
specif
antibodi
complement
mechan
reaction
discuss
detail
section
emphasi
given
work
homolog
human
system
measl
virusinfect
cell
particular
envelop
virus
free
virion
also
serv
target
antibodyand
complementmedi
lysi
topic
review
cooper
welsh
complement
human
complement
system
compos
plasma
protein
includ
intrins
compon
protein
regul
activ
pathway
mechan
system
activ
produc
membran
lesion
mediat
biolog
effect
rel
well
understood
mechan
activ
classic
pathway
miillereberhard
mechan
membran
attack
pathway
produc
membran
lesion
podack
miillereberhard
review
recent
altern
pathway
complement
activ
subject
review
volum
schreiber
miillereb
hard
point
relev
present
discuss
mention
activ
classic
pathway
usual
depend
interact
fc
portion
igg
igm
complex
antigen
c
l
q
subunit
c
activ
enzym
catalyz
assembl
classic
pathway
convertas
sequenti
proteolyt
cleavag
cleavag
associ
give
classic
pathway
convertas
altern
pathway
complement
activ
consist
six
protein
factor
b
p
l
h
inactiv
properdin
current
evid
indic
initi
altern
pathway
surfac
known
activ
rabbit
erythrocyt
fearon
austen
pangbum
miillereberhard
zymosan
fearon
austen
certain
strain
escherichiu
coli
occur
fluid
phase
bound
rel
protect
serum
inactiv
probabl
low
level
background
gener
interact
nativ
factor
b
factor
fluid
phase
surfac
nonactiv
inactiv
rapidli
inactiv
wherea
access
bound
surfac
activ
restrict
factor
b
bind
cleav
factor
gener
altern
pathway
convertas
csbbb
activ
site
bb
fragment
factor
b
amplif
turnov
surfac
deposit
acquisit
cleav
activ
occur
nativ
properdin
bind
retard
otherwis
rapid
decay
enzym
activ
properdin
thu
regulatori
protein
requir
initi
pathway
see
schreiber
miillereberhard
volum
detail
consequ
upon
activ
either
pathway
cleav
membran
attack
complex
assembl
complex
insert
lipid
bilay
cell
membran
dimer
bieseck
et
al
give
typic
electron
microscop
complement
membran
lesion
osmot
lysi
cell
result
either
hydrophil
protein
channel
creat
insert
membran
attack
complex
insert
result
rearrang
phospholipid
creation
lipid
channel
bilay
podack
miillereberhard
tabl
rawl
tompkin
report
demonstr
convincingli
cell
infect
varieti
rna
dna
virus
suscept
lysi
antibodi
complement
howev
heterolog
sera
particularli
rabbit
serum
frequent
use
complement
sourc
may
contain
natur
antibodi
react
heterolog
cell
surfac
viral
antigen
exampl
rawl
tompkin
found
rabbit
serum
complement
sourc
lyse
certain
hsvinfect
cell
presenc
antibodi
wherea
guinea
pig
human
serum
prozon
phenomenon
often
observ
rabbit
guinea
pig
serum
complement
sourc
ehrnst
hick
et
al
particular
problem
princip
purpos
assay
potenti
cytotox
antivir
antibodi
number
studi
tabl
instanc
cytotox
test
hla
typ
summari
earlier
studi
antibodyand
complementdepend
lysi
virusinfect
cell
heterolog
sourc
antibodi
complement
use
studi
design
primarili
detect
cell
surfac
viral
antigen
antibodi
rather
analyz
mechan
cell
lysi
sspe
subacut
scleros
panenceph
ing
presenc
natur
antibodi
complement
sourc
often
use
rig
system
produc
maximum
lysi
ferron
et
al
howev
presenc
natur
antibodi
make
difficult
analyz
mechan
antibodyand
complementmedi
lysi
virusinfect
cell
thu
use
heterolog
system
provid
result
doubt
relev
situat
uiuo
lysi
virusinfect
human
cell
human
serum
studi
detail
homolog
system
oldston
cooper
colleagu
perrin
et
al
sisson
et
al
addit
obviou
direct
relev
human
infect
use
homolog
system
avoid
problem
inher
use
heterolog
sera
complement
sourc
refer
lysi
human
serum
cell
infect
hsv
type
influenza
parainfluenza
mump
measl
virus
depend
presenc
serum
igg
antibodi
specif
relev
viru
complement
review
oldston
lampert
addit
infect
human
epithelioid
cell
line
hela
hep
virusinfect
lymphoblastoid
neural
glial
cell
line
human
origin
also
lyse
lysi
occur
serum
agammaglobulinem
children
despit
intact
complement
system
serum
lack
antibodi
particular
viru
would
lyse
cell
infect
viru
would
addit
igg
contain
specif
antibodi
viru
acquisit
serum
abil
lyse
virusinfect
cell
demonstr
immun
mump
viru
measl
viru
individu
without
preexist
antibodi
sera
obtain
immun
day
would
lyse
infect
cell
becam
abl
produc
specif
lysi
mump
viru
measl
virusinfect
cell
day
afterward
maximum
lytic
abil
attain
day
immun
unpublish
observ
consist
find
studi
requir
intact
altern
pathway
complement
activ
human
serum
lysi
occur
perrin
et
al
sisson
et
al
thu
abil
serum
lyse
virusinfect
cell
extrem
sensit
dilut
cytolyt
activ
lost
dilut
abrog
heat
serum
inactiv
factor
b
contrast
lysi
still
occur
serum
egta
mm
select
chelat
thu
inactiv
classic
pathway
depend
intact
altern
pathway
confirm
use
human
sera
immunochem
deplet
specif
complement
compon
affin
column
chromatographi
monospecif
antisera
coupl
sepharos
perrin
et
az
lysi
cell
infect
mump
herp
simplex
influenza
measl
virus
human
sera
contain
igg
antibodi
measl
viru
immunochem
deplet
variou
complement
compon
affin
chromatographi
except
obtain
patient
genet
defici
deplet
sera
reconstitut
physiolog
concentr
purifi
deplet
compon
lysi
assess
eosin
microcytotox
assay
data
repres
result
three
experi
spontan
lysi
infect
cell
mem
lysi
uninfect
hela
cell
reagent
mean
sd
similar
addit
experi
cell
infect
mump
influenza
parainfluenza
hsv
type
lyse
antibodi
factor
bdeplet
serum
reconstitut
factor
b
restor
lysi
see
perrin
et
al
sisson
et
al
complet
abrog
serum
thu
deplet
factor
b
factor
diminish
properdindeplet
serum
reconstitut
deplet
compon
physiolog
concentr
purifi
protein
restor
lytic
abil
case
see
tabl
sisson
et
al
contrast
serum
immunochem
deplet
genet
defici
compon
necessari
format
classic
pathway
convertas
ca
effici
whole
serum
lyse
measl
virusinfect
cell
furthermor
dose
relat
lysi
curv
show
deplet
serum
measl
viru
antibodi
quantit
equal
origin
whole
serum
abil
lyse
antibodi
coat
measl
virusinfect
cell
fig
kinet
lysi
whole
serum
also
ident
fig
sisson
et
al
observ
thu
show
lysi
virusinfect
cell
human
serum
depend
antibodi
altern
compl
serum
immunochem
deplet
serum
imniunochem
deplet
factor
b
uninfect
cell
infect
cell
without
antibodi
lyse
sisson
et
al
ment
pathway
lack
requir
show
activ
classic
pathway
necessari
lysi
altern
pathway
must
therefor
initi
mechan
recruit
consequ
classic
pathway
activ
report
studi
lysi
virusinfect
cell
human
serum
hick
et
al
report
lysi
measl
virusinfect
monkey
vero
cell
antibodi
human
serum
specif
lysi
observ
mgz
egtatr
serum
serum
heat
adsorb
zymosan
although
none
effect
whole
serum
author
therefor
conclud
lysi
could
mediat
altern
classic
pathway
neither
pathway
alon
effect
deplet
serum
serum
use
time
point
sisson
et
al
combin
human
serum
produc
lysi
absenc
antibodi
studi
find
classic
pathway
mediat
lysi
contrast
find
discuss
probabl
relat
use
differ
cell
line
heterolog
system
absolut
requir
antibodi
complementmedi
lysi
virusinfect
cell
serum
document
amount
cell
bound
antibodi
requir
induc
lysi
determin
use
measl
virusinfect
hela
cell
target
employ
bind
assay
radiolabel
igg
n
lysi
occur
mean
greater
x
x
molecul
igg
bound
per
infect
cell
perrin
et
al
sisson
et
al
fig
larg
amount
igg
although
measl
viru
infect
hela
cell
larg
surfac
area
f
ab
fragment
igg
also
induc
lysi
mump
virusand
measl
virusinfect
cell
dose
relat
lysi
curv
whole
igg
f
ab
whole
deplet
serum
nearident
sisson
et
al
howev
fab
fragment
ineffect
induc
lysi
least
time
fab
f
ab
igg
molecul
bound
per
infect
cell
requir
produc
lysi
maximum
attain
fab
experi
high
densiti
difficult
exclud
possibl
fab
fragment
reassoci
despit
initi
alkyl
see
fig
sisson
et
al
experi
thu
show
requir
dival
antibodi
requir
fc
portion
igg
induc
lysi
virusinfect
cell
altern
pathway
fact
f
ab
bind
c
l
q
effect
whole
igg
proof
lack
requir
classic
pathway
activ
lysi
fab
fab
addit
f
ab
fragment
report
abl
induc
lysi
measl
virusinfect
cell
one
studi
rabbit
guinea
pig
sera
use
complement
sourc
find
difficult
interpret
heterolog
complement
sourc
use
determin
made
amount
fab
bound
cell
contrast
fab
fragment
block
lysi
hsvinfect
cell
b
igg
antibodi
rabbit
complement
studi
brier
et
ul
requir
dival
homolog
human
system
suggest
antibodyinduc
redistribut
viral
antigen
cell
membran
may
requir
product
lysi
prevent
cap
cytochalasin
sodium
azid
abrog
complementmedi
lysi
howev
inhibitor
actin
polymer
prevent
local
patch
viral
antigen
cell
membran
b
antibodi
antibodi
direct
differ
viral
polypeptid
express
cell
surfac
mediat
lysi
measl
virusinfect
cell
measl
viru
two
surfac
glycoprotein
ha
f
use
persist
infect
cell
line
heterolog
complement
sourc
ehrnst
report
antibodi
ha
induc
lysi
altern
pathway
wherea
antibodi
f
induc
lysi
classic
pathway
amount
antibodi
bound
per
cell
determin
experi
immunoprecipit
sdspage
analysi
infect
cell
antisera
use
ehrnst
monospecif
j
g
p
sisson
b
oldston
unpublish
observ
make
result
best
difficult
interpret
contrast
use
cell
surfac
label
immunoprecipit
assess
site
antibodi
bind
acut
infect
cell
sisson
et
ul
found
human
igg
antibodi
bound
specif
ha
f
protein
equal
effect
induc
lysi
altern
pathway
serum
neither
antibodi
would
induc
lysi
classic
pathway
alon
factor
bdeplet
serum
equival
amount
antibodi
bound
either
viral
polypeptid
induc
equal
degre
lysi
subclass
igg
seem
unlik
direct
import
induct
lysi
especi
sinc
fc
region
requir
although
experi
indic
iggl
major
subclass
virtual
inform
whether
human
immunoglobulin
class
induc
complementdepend
lysi
virusinfect
cell
would
interest
insofar
virus
induc
earli
igm
respons
primari
infect
immun
may
also
produc
serum
iga
respons
joseph
et
al
report
amount
equival
greater
cytolyt
igg
iga
igm
isol
convalesc
sera
patient
measl
vaccin
unpublish
observ
induc
lysi
measl
virusinfect
cell
howev
might
expect
measl
viru
antibodi
titer
igm
iga
prepar
low
compar
titer
igg
fraction
rabbit
igm
antibodi
appear
rel
ineffect
induc
lysi
virusinfect
cell
compar
igg
brier
et
al
ehrnst
precis
molecular
mechan
antibodi
produc
lysi
virusinfect
cell
conjunct
complement
remain
determin
howev
find
describ
next
section
show
igg
requir
initi
altern
pathway
measl
virusinfect
cell
although
requir
cell
lysi
recent
work
confirm
role
altern
pathway
lyse
virusinfect
cell
experi
use
measl
virusinfect
hela
cell
repres
model
altern
pathway
complement
activ
recent
assembl
vitro
isol
constitu
protein
highli
purifi
form
mixtur
compos
factor
b
nativ
properdin
two
control
protein
ina
physiolog
concentr
mediat
deposit
onto
activ
altern
pathway
rabbit
erythrocyt
effici
equal
serum
schreiberet
al
addit
mixtur
five
purifi
protein
membran
attack
pathway
creat
system
cytolyt
capac
purifi
cytolyt
altern
pathway
lyse
rabbit
erythrocyt
lysosym
e
coli
effici
ccdeplet
serum
schreiber
mullereberhard
schreiber
et
al
recent
experi
shown
purifi
cytolyt
altern
pathway
could
lyse
antibodyco
measl
virusinfect
cell
effici
compar
ccdeplet
whole
human
serum
serum
lysi
occur
absenc
antibodi
f
ab
z
igg
gave
near
ident
dose
relat
lysi
curv
fab
produc
lysi
approxim
x
molecul
igg
f
ab
bound
per
infect
cell
requir
induc
lysi
sisson
et
al
see
fig
omiss
properdin
purifi
cytolyt
altern
pathway
total
abrog
lysi
measl
virusinfect
cell
noteworthi
insofar
properdin
essenti
lysi
rabbit
erythrocyt
e
coli
purifi
cytolyt
altern
pathway
schreiber
miillereberhard
schreiber
et
al
differ
may
well
reflect
fact
nucleat
cell
requir
complementmedi
membran
damag
produc
lysi
use
system
compos
highli
purifi
complement
protein
provid
conclus
evid
known
protein
altern
membran
attack
pathway
igg
antibodi
suffici
lysi
measl
virusinfect
cell
without
serum
factor
find
efficaci
f
ab
also
exclud
possibl
altern
pathway
activ
antibodyco
virusinfect
cell
could
occur
bypass
activ
pathway
describ
may
frank
sheep
erythrocyt
bear
rabbit
antibodi
appar
initi
altern
pathway
mechan
involv
henc
domin
role
establish
altern
pathway
complementdepend
lysi
virusinfect
cell
human
serum
requir
specif
antibodi
intact
altern
pathway
lysi
virusinfect
cell
first
suggest
antibodi
might
requir
activ
altern
pathway
system
would
distinctli
unusu
activ
altern
pathway
known
particul
activ
rabbit
erythrocyt
zymo
found
measl
virusinfect
hela
cell
incub
mixtur
highli
purifi
factor
b
nativ
properdin
p
l
h
ina
purifi
altern
pathway
complement
activ
without
show
progress
linear
uptak
onto
cell
surfac
fig
uptak
averag
x
molecul
per
cell
minut
specif
shown
uninfect
hela
cell
block
edta
measl
virusinfect
hela
cell
also
show
progress
uptak
human
serum
immunochem
deplet
igg
addit
independ
igg
uptak
purifi
altern
pathway
onto
measlesinfect
cell
absenc
antibodi
also
independ
properdin
rate
uptak
absenc
presenc
properdin
similar
rate
uptak
infect
cell
presenc
igg
absenc
properdin
experi
summar
fig
thu
rate
uptak
infect
cell
increas
presenc
igg
properdin
togeth
igg
properdin
also
requir
lysi
suggest
interact
two
possibl
affect
rate
uptak
import
mediat
lysi
experi
signific
uptak
measl
virusinfect
cell
first
demonstr
hour
infect
time
cell
express
viral
polypeptid
surfac
indic
viral
replic
must
occur
altern
pathway
activ
becom
detect
experi
absolut
amount
ultim
bound
infect
cell
alon
similar
ident
amount
bound
infect
cell
coat
igg
rate
uptak
influenc
igg
work
need
determin
whether
abil
activ
sisson
et
al
altern
pathway
independ
antibodi
gener
properti
cell
infect
vivs
howev
note
number
human
lymphoblastoid
cell
line
activ
altern
pathway
human
serum
budzko
et
al
theofilopoulo
perrin
mcconnel
lachmann
mcconnel
et
al
mcconnel
et
al
report
abil
correl
transform
epsteinbarr
eb
viru
found
cell
line
posit
eb
virusdetermin
nuclear
antigen
ebna
activ
pathway
shown
convers
mgegta
serum
deposit
cell
detect
immunofluoresc
ebna
neg
line
deposit
membran
acquir
abil
eb
viru
transform
acquisit
ebna
eb
virustransform
cell
mostli
nonproduc
express
detect
structur
viral
antigen
surfac
presum
must
chang
membran
shown
presenc
uncharacter
lymphocytedetermin
niembran
antigen
svedmyr
jondal
despit
abil
raji
cell
one
ebnaposit
lymphoblastoid
line
activ
altern
pathway
lysi
cell
occur
prolong
incub
serum
hour
independ
antibodi
theofilopoulo
perrin
contrast
measl
virusinfect
hela
cell
lyse
measur
specif
releas
even
hour
incub
serum
without
antibodi
viru
j
g
p
sisson
unpuhlish
observ
support
less
direct
evid
suggest
ineasl
virusinfect
cell
hick
et
sendai
virusinfect
cell
okada
et
activ
altern
pathway
impli
lysi
guinea
pig
serum
independ
antibodi
also
suggest
retrovirusinfect
cell
activ
altern
pathway
evidenc
hy
use
mgegta
serum
roset
assay
detect
cellbound
okada
baba
howev
seem
equal
like
retrovirusinfect
cell
might
activ
classic
pathway
sinc
alreadi
known
free
retroviru
activ
classic
pathway
independ
antibodi
b
bind
c
l
q
via
surfac
glycoprotein
welsh
et
al
cooper
et
al
bartholomew
et
az
princip
aspect
target
cell
affect
lysi
densiti
present
viral
antigen
express
cell
surfac
factor
decreas
surfac
antigen
express
tend
decreas
suscept
lysi
thu
event
caus
virusinfect
cell
produc
mutant
defect
surfac
glycoprotein
defect
interf
viru
suppress
replic
standard
viru
result
diminish
viral
antigen
express
cell
surfac
welsh
oldston
found
suscept
cultur
neuroblastoma
cell
infect
lcmv
lysi
antivir
antibodi
heterolog
complement
declin
increas
time
cultur
relat
diminish
lcmv
surfac
antigen
express
result
gener
defect
interf
lcmv
resist
lysi
specif
lcmv
acut
persist
infect
cell
still
suscept
lysi
complement
antigen
modul
measl
virusinfect
cell
antibodi
describ
section
also
render
cell
resist
human
antibodyand
complementmedi
lysi
joseph
oldston
found
hour
cultur
presenc
antibodi
cell
acut
persist
infect
measl
viru
lost
suscept
antibodyand
complementdepend
lysi
certain
dose
addit
interferon
cultur
cell
express
lcmv
antigen
follow
reduct
express
viral
antigen
cell
surfac
suscept
immun
lysi
b
oldston
merigan
unpublish
observ
mechan
wherebi
infect
target
cell
could
escap
lysi
antibodi
complement
express
new
membran
protein
block
access
antibodi
surfac
antigen
celi
et
al
show
murin
myeloma
cell
grown
ascit
tumor
express
increas
amount
surfac
glycoprotein
seem
abl
block
bind
cytotox
antibodi
antigen
remov
protein
proteas
restor
suscept
immun
lysi
complement
cytotox
lymphocyt
whether
similar
event
occur
viral
antigen
unknown
cell
cycl
also
influenc
suscept
lysi
cike
friberg
found
moloney
virustransform
lymphocyt
suscept
lysi
antibodi
complement
phase
yet
viral
antigen
present
access
antibodi
complement
activ
throughout
cell
cycl
lemer
et
al
complement
membran
lesion
also
present
cell
differ
phase
cell
cycl
although
immun
lysi
restrict
consequ
plasma
membran
may
vari
abil
withstand
complementmedi
damag
variou
phase
cell
cycl
presum
factor
affect
membran
repair
suscept
nucleat
cell
gener
complementmedi
lysi
probabl
relat
part
abil
effect
membran
repair
instanc
complex
chang
synthesi
releas
sever
lipid
class
report
tumor
cell
line
upon
exposur
antibodi
complement
schlager
et
al
howev
direct
inform
viru
infect
affect
cell
abil
repair
membran
summari
cell
infect
number
differ
rna
dna
bud
virus
lyse
human
serum
lysi
depend
igg
antibodi
altern
pathway
complement
detail
studi
use
measl
viru
shown
f
ab
effect
whole
igg
induc
lysi
fab
ineffect
furthermor
igg
requir
activ
altern
pathway
occur
surfac
measl
virusinfect
cell
independ
antibodi
properdin
requir
activ
altern
pathway
requir
igg
lysi
infect
cell
major
remain
question
concern
mechan
reaction
follow
cell
infect
virus
activ
altern
pathway
virusinfect
cell
activ
altern
pathway
mechan
igg
induc
lysi
mechan
measl
virusinfect
cell
activ
altern
pathway
may
similar
describ
activ
activatorbound
protect
propos
specif
surfac
molecul
activ
particl
might
act
plh
antagonist
restrict
access
pangburn
mullereberhard
pangburn
et
al
conceiv
viral
glycoprotein
insert
membran
integr
membran
protein
could
function
way
altern
virusinduc
chang
membran
may
respons
exampl
viru
infect
could
result
express
releas
membran
proteas
might
cleav
immunoelectron
microscopi
studi
measl
virusinfect
cell
incub
human
serum
contain
antibodi
measl
stain
ferritinconjug
antisera
factor
b
properdin
show
antisera
bound
viral
antigenantibodi
complex
cell
membran
adjac
site
membran
viral
spike
appar
show
label
antibodi
bind
suggest
membran
deposit
occur
site
insert
viral
glycoprotein
oldston
lampert
fact
properdin
requir
activ
pathway
measl
virusinfect
cell
accord
known
function
delay
intrins
decay
properdin
recruit
multipl
molecul
deposit
surfac
close
spatial
associ
activ
pathway
must
therefor
preced
recruit
fearon
austen
medicu
et
al
requir
properdin
complementdepend
lysi
measl
virusinfect
cell
contrast
nonessenti
role
lyse
activ
may
reflect
fact
nucleat
cell
capac
membran
repair
requir
extens
complementmedi
membran
damag
lysi
result
properdin
would
expect
enhanc
c
turnov
membran
deposit
fact
virusinfect
cell
lyse
antibodi
classic
pathway
alon
human
serum
requir
explan
classic
pathway
actiuat
igg
antibodi
bound
virusinfect
cell
shown
uptak
assess
b
immunofluoresc
factor
bdeplet
serum
bind
follow
assembl
c
surfac
igg
bear
measlesinfect
cell
k
pangburn
j
g
p
sisson
unpublish
observ
howev
known
whether
membran
lesion
result
possibl
despit
activ
classic
pathway
insuffici
membran
damag
occur
achiev
lysi
absenc
amplif
provid
altern
pathway
feedback
mechan
mechan
wherebi
igg
induc
lysi
altern
pathway
remain
determin
requir
dival
antibodi
suggest
patch
viral
polypeptid
membran
may
import
fact
rate
uptak
onto
measlesinfect
cell
enhanc
igg
properdin
present
suggest
igg
may
facilit
uptak
properdin
experi
need
test
possibl
instanc
antibodi
altern
pathway
requir
lyse
cell
human
lymphocyt
coat
human
alloantisera
lyse
altern
pathway
human
serum
although
alloantisera
use
studi
abil
effect
induc
lysi
classic
pathway
ferron
et
al
trypanosornu
cruzii
also
lyse
igg
antibodi
altern
pathway
krettli
nussenzweig
addit
evid
suggest
serum
factor
probabl
igg
enhanc
altern
pathwaydepend
lysi
rabbit
erythrocyt
human
serum
polhil
et
al
nelson
ruddi
although
igg
essenti
reaction
appar
consider
surfacebound
igg
requir
induc
complementdepend
lysi
virusinfect
cell
requir
antigen
modul
antibodydepend
cellmedi
cytotox
possibl
implic
discuss
section
v
work
show
cell
infect
virus
activ
altern
pathway
independ
antibodi
would
strengthen
evid
view
altern
pathway
mean
nonspecif
host
defens
microorgan
also
import
determin
whether
free
virus
activ
pathway
observ
wedgewood
et
al
welsh
suggest
newcastl
diseas
viru
may
inactiv
altern
pathway
independ
antibodi
human
serum
review
cooper
welsh
main
emphasi
review
direct
toward
effect
antibodi
alon
antibodi
complement
virusinfect
cell
discuss
antibodydepend
cellmedi
cytotox
adcc
briefli
illustr
rang
action
antibodi
may
virusinfect
cell
place
action
antibodi
compar
context
section
deal
adcc
appli
virusinfect
cell
emphasi
human
system
role
antibodi
rather
detail
discuss
effector
cell
involv
adcc
studi
number
differ
system
review
mclennan
perlmann
et
al
lovchik
hong
perlmann
cerottini
although
lysi
antibodyco
erythrocyt
mediat
phagocyt
cellspolymorphonuclear
leukocyt
pml
macrophagesth
lysi
nucleat
cell
sensit
antibodi
nonimmun
human
peripher
blood
lymphocyt
pbl
mediat
predominantli
lymphocyt
fc
receptor
cell
convent
b
lymphocyt
marker
surfac
ig
sheep
erythrocyt
e
rosett
neg
thu
fall
within
null
cell
popul
howev
evid
pbl
abl
mediat
adcc
found
subpopul
cell
fc
receptor
igg
see
perlmann
cerottini
also
report
virusinfect
target
cell
subset
also
contain
cell
abl
suppress
antibodi
product
b
cell
moretta
et
al
although
cell
mediat
adcc
often
refer
k
cell
function
definit
base
presenc
uniqu
surfac
marker
adcc
usual
rapid
membran
damag
detect
minut
reaction
incept
cell
lysi
usual
complet
hour
evid
suggest
effector
cell
inactiv
interact
target
ziegler
henney
may
result
modul
fc
receptor
effector
cell
surfac
perlmann
cerottini
assay
adcc
exogen
antibodi
convent
ad
cytotox
assay
presenc
pbl
howev
pbl
exhibit
cytotox
rang
target
cell
absenc
ad
antibodi
activ
mediat
part
class
cell
function
design
natur
killer
nk
cell
uncertainti
whether
spontan
natur
cytotox
could
depend
small
amount
antibodi
present
assay
system
reason
recent
observ
concern
human
nk
cell
summar
spontan
cytotox
exhibit
unsensit
human
pbl
variou
cultur
cell
line
virusinfect
cell
uitro
receiv
increas
attent
lysi
mediat
nk
cell
recent
review
human
herberman
et
al
saksela
et
al
perlmann
cerottini
murin
herberman
et
al
kiessl
et
al
welsh
system
bulk
evid
indic
human
nk
cell
easili
separ
cell
mediat
adcc
chiefli
null
cell
fc
receptor
deplet
nk
cell
target
bind
cross
competit
experi
suggest
cell
popul
mediat
activ
howev
mechan
target
recognit
differ
function
distinct
cell
mediat
adcc
nk
activ
made
basi
avail
evid
summar
review
suggest
nk
cell
recogn
bind
target
cell
via
fc
receptor
depend
antibodi
cytotox
furthermor
nk
cell
exhibit
convent
immunolog
specif
lyse
wide
rang
infect
uninfect
target
cell
contrast
cell
mediat
adcc
recogn
bind
target
cell
sensit
antibodi
via
fc
receptor
requir
antibodi
cytotox
thu
confer
immunolog
specif
reaction
obviou
import
question
whether
small
amount
igg
antibodi
secret
cours
cytotox
assay
bound
cytotox
cell
via
fc
herberman
et
al
viuo
huddleston
et
al
howev
clear
whether
interferon
also
enhanc
abil
pbl
mediat
c
c
herberman
et
al
virusinfect
cell
tumorand
virustransform
cell
line
induc
interferon
releas
pbl
interferon
enhanc
activ
nk
cell
within
pbl
popul
contribut
lysi
target
cell
cours
cytotox
assay
santoli
et
al
thu
distinguish
nk
cell
activ
c
c
present
difficulti
unless
care
defin
reagent
use
block
iggfc
receptor
interact
uninfect
infect
cell
target
difficult
interpret
rel
import
lysi
virusinfect
cell
pbl
nk
activ
induc
vitro
interferon
releas
cytotox
assay
cytotox
maxim
hour
wherea
c
c
presenc
exogen
ad
antibodi
usual
maxim
hour
howev
kill
nk
cell
alreadi
induc
preexposur
interferon
vivo
vitro
maxim
hour
wherea
adcc
depend
antibodi
secret
vitro
assay
might
expect
slower
kinet
henc
clearli
distinguish
nk
cytotox
adcc
basi
kinet
also
difficult
possibl
cell
involv
nk
cell
kill
adcc
current
evid
suggest
attach
target
cell
sensit
antibodi
via
fc
receptor
may
induc
effici
cytotox
mechan
bind
via
put
nk
cell
receptor
mechan
c
c
appear
differ
cell
infect
varieti
virus
unlik
differ
involv
c
c
nucleat
cell
although
numer
descript
virusinfect
cell
kill
human
pbl
report
c
c
activ
deliber
assay
addit
exogen
antibodi
discuss
first
exampl
concern
c
c
hsvinfect
cell
human
pbl
shore
et
al
shore
et
al
ragerzisman
bloom
well
mous
periton
exud
cell
ragerzisman
bloom
report
emphas
c
c
could
produc
antibodi
concentr
sever
hundredfold
less
need
produc
antibodi
complement
depend
lysi
virusinfect
cell
extend
find
shore
et
al
kohl
et
al
note
effector
cell
human
pbl
popul
could
either
adher
cell
nonadher
fc
receptorposit
lymphocyt
adher
cell
requir
higher
antibodi
concentr
display
slower
kinet
kill
nonadher
cell
report
adher
mononuclear
cell
mediat
adcc
virusinfect
cell
human
system
other
found
elimin
adher
cell
diminish
might
enhanc
adcc
studi
hsv
mollerlarssen
et
suggest
trace
amount
antibodi
present
medium
use
wash
pbl
could
mediat
adcc
pbl
absenc
ad
igg
ad
complic
hsvinduc
fc
receptor
discuss
section
recal
lysi
hsvinfect
cell
may
occur
part
interact
involv
receptor
ragerzisman
et
al
suggest
even
trace
aggreg
igg
fetal
bovin
serum
could
crosslink
target
mous
periton
effector
cell
fc
receptor
produc
appar
adcc
hsv
infect
cell
although
possibl
nk
cell
kill
consid
studi
mump
virusinfect
cell
anderson
et
al
harfast
et
al
high
concentr
rabbit
antibodi
mump
viru
inhibit
lower
concentr
enhanc
pblmediat
cytotox
antibodi
independ
viru
specif
cytotox
mediat
fc
receptor
bear
pbl
also
note
studi
harfast
et
al
sever
laboratori
independ
assay
pblmediat
kill
measl
virusinfect
target
antibodi
measl
viru
enhanc
kill
measl
virusinfect
cell
pbl
harvest
normal
immun
subject
perrin
et
al
kreth
ter
meulen
ewan
lachmann
antibodi
normal
immun
subject
patient
subacut
scleros
panenceph
sspe
also
enhanc
cytotox
pbl
obtain
patient
sspe
kreth
ter
meulen
perrin
et
al
tishon
j
h
huddleston
b
oldston
unpublish
observ
sinc
patient
sera
enhanc
cytotox
observ
varianc
earlier
report
ahm
et
block
factor
sera
sspe
patient
inhibit
lymphocytemedi
activ
migrat
inhibit
prolifer
measl
virusinfect
cell
although
ahm
et
al
assay
cytotox
perrin
et
al
calcul
averag
x
antibodi
molecul
bound
per
measl
virusinfect
target
hela
cell
requir
induc
adcc
contrast
much
greater
least
amount
cellbound
antibodi
requir
induc
antibodyand
complementdepend
lysi
system
see
section
iv
respiratori
syncyti
virusinfect
cell
lyse
adcc
scott
et
al
use
colostrum
well
serum
sourc
igg
antibodi
adcc
also
use
detect
igg
antibodi
e
b
viru
jondal
lytic
infect
cell
express
virusspecif
surfac
antigen
transform
cell
use
target
c
summari
conclus
clear
addit
specif
antibodi
enhanc
cytotox
pbl
virusinfect
cell
minim
amount
antibodi
effect
adcc
activ
kinet
adcc
usual
rapid
increas
ionic
efflux
target
cell
observ
minut
system
ziegler
henney
seem
unlik
antibodi
would
produc
signific
modul
cours
cytotox
assay
nevertheless
possibl
inhibitori
effect
high
dose
antibodi
adcc
might
relat
cap
redistribut
viral
antigen
antibodi
inhibit
might
also
produc
modul
loss
fc
receptor
effector
cell
aggreg
igg
perlniann
cerottini
igg
antibodi
respons
adcc
virusinfect
cell
human
studi
cite
present
publish
work
rel
efficaci
antibodi
direct
differ
viral
antigen
determin
cell
surfac
mediat
adcc
howev
unpublish
work
laboratori
l
h
perrin
b
oldston
suggest
may
differ
abil
antibodi
measl
viru
ha
antibodi
measl
viru
f
protein
produc
adcc
spontan
cytotox
b
n
k
cell
involv
recognit
target
antigen
receptor
distinct
fc
receptor
cell
within
null
cell
popul
conceiv
antivir
antibodi
target
cell
surfac
might
steric
hinder
bind
cell
target
antigen
whatev
antigen
infect
cell
antibodi
might
thu
inhibit
n
k
cell
bind
simultan
facilit
k
cell
bind
number
report
evalu
spontan
cytotox
human
pbl
virusinfect
target
without
ad
antibodi
select
report
discuss
indic
possibl
role
antibodi
case
evid
cytotox
depend
antibodi
adsorb
effector
cell
suggest
studi
greenberg
et
ul
influenza
mollerlarssen
et
hsv
altern
explan
would
antibodi
produc
plasma
cell
cours
cytotox
assay
vaccin
human
subject
measl
viru
vaccinia
viru
perrin
et
al
perrin
et
al
found
cytotox
pbl
gener
enhanc
lysi
virusinfect
target
b
pbl
began
day
peak
day
rapidli
dissip
day
immun
induc
cytotox
pbl
show
immun
specif
pbl
gener
vaccin
measl
viru
kill
measl
virusinfect
target
cell
preferenti
vaccinia
virusinfect
target
similarli
cytotox
pbl
gener
vaccinia
vaccin
show
enhanc
kill
vacciniainfect
target
measl
virusinfect
target
target
cell
use
autolog
fibroblast
homolog
xenogen
cultur
cell
line
pbl
cytotox
induc
measl
viru
vaccinia
viru
vaccin
mediat
cell
eroset
cell
fc
receptor
posit
e
rosett
neg
cell
specif
cytotox
virusinfect
target
cell
inhibit
f
ab
antihuman
igg
experi
use
differ
subset
pbl
immun
nonimmun
subject
show
fc
receptor
bear
lymphocyt
either
immun
nonimmun
person
lyse
virusinfect
target
presenc
b
cell
immun
donor
henc
two
popul
within
pbl
particip
kill
virusinfect
target
addit
fc
receptor
posit
effector
lymphocyt
like
b
lymphocyt
produc
antibodi
present
evid
antibodi
play
role
circumst
compel
synthes
antibodi
identifi
directli
howev
pbl
subject
day
immun
natur
infect
influenza
viru
recent
shown
secret
specif
antibodi
viral
hemagglutinin
vitro
coincid
peak
cytotox
pbl
influenza
infect
target
cell
greenberg
et
al
howev
instanc
enhanc
cytotox
virusinfect
target
shown
human
pbl
absenc
ad
antibodi
like
result
interferoninduc
nk
cell
activ
santoli
koprowski
abund
evid
indic
effector
cell
mediat
adcc
viru
infect
target
mediat
adcc
nucleat
cell
target
human
pbl
name
nonadher
cell
fc
receptor
rosett
sheep
e
report
adher
cell
mediat
adcc
hsvinfect
target
cell
kohl
et
al
could
relat
special
circumst
hsv
system
howev
studi
cytotox
adher
cell
studi
directli
ineffect
indirectli
deduc
f
x
deplet
pbl
diminish
cytotox
b
remain
pbl
human
adher
mononuclear
cell
reportedli
mediat
adcc
uninfect
sensit
nucleat
target
cell
honvitz
et
al
rous
igg
antibodi
highli
effici
abil
sensit
virusinfect
cell
lysi
human
pbl
amount
cellbound
specif
antivir
antibodi
requir
adcc
least
less
requir
antibodydepend
complementmedi
cytotox
kinet
adcc
faster
modul
present
virusinfect
human
target
model
evid
complement
potenti
adcc
activ
although
precis
assess
role
adcc
cytotox
assay
complic
presenc
nk
cell
activ
lymphocyt
popul
adcc
appear
effici
cytotox
mechan
uitro
nk
cell
cytotox
rel
role
adcc
vivo
man
acut
viral
infect
well
nk
cell
induc
interferon
cytotox
cell
remain
determin
ampl
evid
vitro
studi
absenc
cytotox
effector
system
antibodi
inhibit
viru
product
prevent
infect
cell
subsequ
immunolog
attack
presenc
complementor
antibodydepend
cytotox
lymphocyt
antibodi
mediat
destruct
virusinfect
cell
type
cytotox
demonstr
vitro
difficult
certain
rel
import
action
vivo
complement
alon
nk
cell
cytotox
cell
macrophag
interferon
potenti
abl
contribut
control
viru
infect
vivo
addit
effect
depend
antibodi
evid
antibodyinduc
viral
antigen
modul
occur
vivo
well
document
tumor
viru
model
allud
section
name
gross
leukemia
viru
aoki
johnson
flv
doig
cheseboro
tl
system
boys
et
al
boys
et
al
evid
loss
surfac
viral
antigen
vivo
despit
presenc
cytoplasm
viral
antigen
reexpress
surfac
antigen
leukem
spleen
cell
affect
anim
transfer
antibodyfre
environ
reason
antigen
modul
rather
immun
jysi
infect
cell
occur
clear
howev
complementmedi
lysi
adcc
rel
ineffici
mous
compar
human
system
instanc
mice
dormant
flv
erythroleukemia
studi
wheelock
et
al
genovesi
et
al
l
defici
addit
antibodi
might
block
cell
cytotox
welsh
oldston
effro
et
al
infect
could
advers
affect
function
cytotox
effector
cell
known
whether
antigen
modul
virusinfect
cell
occur
vivo
man
howev
one
situat
possibl
relev
vitro
antigen
modul
measlesinfect
cell
diseas
subacut
scleros
panenceph
sspe
sspe
rare
diseas
character
chronic
progress
brain
damag
afflict
children
young
adult
measl
viru
isol
predominantli
brain
lymphoid
tissu
cocultiv
techniqu
electron
microscopi
show
accumul
measl
viral
nucleocapsid
brain
cell
ter
meulen
et
al
thu
sspe
persist
measl
viru
infect
man
reason
latent
period
sever
year
typic
measl
viru
infect
insidi
onset
sspe
well
local
brain
unknown
patient
sspe
high
titer
antibodi
measl
sera
cerebrospin
fluid
csf
evid
impair
antibodi
complement
kill
joseph
et
al
adcc
kreth
ter
meulen
perrin
et
al
measl
virusinfect
target
cell
csf
detect
hemolyt
complement
either
normal
subject
patient
sspe
postul
presenc
antibodi
absenc
complement
pauciti
cytotox
lymphocyt
local
area
central
nervou
system
antibodi
could
modul
viral
antigen
express
infect
cell
surfac
could
prevent
cell
fusion
death
initi
state
viral
persist
condit
would
provid
select
pressur
favor
emerg
mutant
virus
temperaturesensit
defect
interf
viru
oldston
experiment
evid
suggest
antibodi
associ
modif
measl
infect
facilit
persist
infect
albrecht
et
found
sspe
isol
produc
chronic
enceph
anim
preexist
antibodi
measl
compar
acut
fatal
diseas
anim
without
antibodi
similarli
wear
rapp
found
matern
antibodi
requir
produc
latent
brain
infect
upon
inocul
newborn
suckl
hamster
adapt
strain
human
measl
viru
hsv
commonli
maintain
latent
state
within
nerv
ganglia
central
nervou
system
suggest
antibodi
hsv
could
maintain
hsv
latenc
infect
ganglia
evidenc
passiv
transfer
antibodi
prevent
reactiv
latent
infect
ganglia
implant
nonimmun
mice
steven
cook
interpret
possibl
exampl
antibodyinduc
antigen
modul
steven
cook
joseph
oldston
other
suggest
addit
mechan
may
maintain
latenc
experi
reactiv
hsv
occur
despit
high
titer
hsv
antibodi
uitro
immunosuppress
mice
openshaw
et
al
allison
although
protect
invari
howev
protect
effect
antibodi
could
result
neutral
free
viru
rather
cytotox
effect
infect
cell
hick
et
al
show
decomplement
cobra
venom
factor
increas
mortal
sever
pneumonia
influenza
mice
diseas
also
sever
anim
despit
serum
neutral
antibodi
respons
equival
control
mechan
whether
direct
lysi
infect
cell
chemotaxi
inflammatori
cell
effect
free
infecti
viru
unknown
evid
tissu
injuri
site
viru
persist
chronic
lcmv
infect
mice
aleutian
diseas
mink
mediat
passiv
transfer
antibodi
oldston
dixon
porter
et
al
decomplement
cobra
venom
factor
protect
death
adult
mice
acut
infect
lcmv
oldston
dixon
igg
demonstr
immunofluoresc
neuron
cell
infect
measl
perivascular
area
brain
patient
sspe
vandvik
jeni
et
type
evid
suggest
antibodi
complement
induc
tissu
damag
react
virusinfect
cell
provid
strongest
evid
antibodym
evid
provid
human
immunodefici
syndrom
suggest
patient
cell
defici
like
develop
sever
infect
common
viral
agent
eg
measl
viru
herp
viru
vaccinia
viru
infect
mani
immunodefici
character
cell
defect
also
accompani
defici
antibodi
product
mani
viral
antigen
depend
henc
antibodi
defici
total
exclud
contribut
sever
viru
infect
circumst
patient
hypogammaglobulinemia
gener
recov
normal
viru
infect
although
whether
small
amount
igg
effect
mediat
adcc
known
patient
defici
seem
unduli
predispos
viru
infect
although
patient
prone
recurr
pyogen
bacteri
infect
lachmann
rosen
nevertheless
passiv
administ
antibodi
clearli
exert
protect
therapeut
effect
number
human
viru
infect
appli
also
immunodefici
patient
contract
vaccinia
viru
varicellazost
viru
infect
pahwa
et
al
review
document
particularli
refer
work
human
system
antibodi
exert
number
signific
effect
virusinfect
cell
igg
antibodi
mediat
destruct
virusinfect
cell
conjunct
complement
cytotox
lymphocyt
addit
conceptu
level
evid
suggest
antibodi
may
enhanc
confer
specif
basic
nonspecif
humor
cellmedi
defens
mechan
thu
virusinfect
cell
activ
altern
complement
pathway
independ
igg
antibodi
requir
subsequ
lysi
cell
similarli
nk
cell
lyse
virusinfect
target
cell
independ
antibodi
without
immunolog
specif
antibodi
enhanc
confer
specif
cytotox
probabl
class
effector
cell
import
reaction
viuo
particularli
comparison
cytotox
cell
remain
uncov
possibl
antibodi
block
cytotox
cell
function
vivo
vitro
welsh
oldston
effro
et
al
zinkernagel
doherti
limit
inform
rel
import
cytotox
mechan
acut
viru
infect
human
futur
collect
analysi
data
area
necessari
final
abil
antibodi
affect
synthesi
intracellular
surfac
express
viral
protein
recent
investig
molecular
basi
alreadi
evid
antibodi
act
level
mechan
may
play
import
role
establish
mainten
viral
persist
